Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its news flow reflects this specialized focus. Company announcements frequently highlight developments related to its three commercial-stage products—EXPAREL, ZILRETTA and iovera°—as well as its gene therapy candidate PCRX-201 for osteoarthritis of the knee.
On this page, readers can follow Pacira news such as commercial partnerships, clinical data, manufacturing updates and shareholder-related events. Recent releases include an agreement granting LG Chem exclusive rights to commercialize EXPAREL in select Asia-Pacific markets, preliminary revenue updates emphasizing EXPAREL sales, and data from a pilot study showing favorable safety and pain reduction with iovera° compared with radiofrequency ablation in chronic low back pain.
Pacira also issues news about its participation in scientific and investor conferences, including presentations at major healthcare conferences, and its involvement in collaborative research efforts. For example, the company announced that it joined the PROBE Consortium, a public‑private initiative using big data and AI to improve osteoarthritis research and care, and that it will contribute data from its ASCEND study of PCRX-201.
In addition, Pacira’s news includes corporate and financial updates such as preliminary unaudited revenue results, share repurchase activity, inducement equity grants under its inducement plan, and operational changes like workforce reductions linked to manufacturing efficiency improvements. External parties such as DOMA Perpetual Capital Management LLC have also issued public letters and proxy-related communications concerning Pacira’s governance and strategic options.
Investors, analysts and healthcare professionals can use this news feed to monitor product performance, pipeline progress, strategic partnerships, financing developments and shareholder actions that may influence the outlook for PCRX stock and Pacira’s role in non-opioid pain management.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has announced a $3 million investment in Spine BioPharma via a convertible note, aimed at advancing Spine's lead candidate, Remedisc™, a novel therapeutic for degenerative disc disease. An additional $7 million investment is contingent upon achieving specific milestones. This initiative aligns with Pacira's commitment to non-opioid pain management, targeting the underlying causes of degenerative disc disease to improve patient outcomes. Remedisc is expected to enter Phase 2/3 trials later this year.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has filed a lawsuit against the American Society of Anesthesiologists (ASA) over misleading studies published in their journal regarding EXPAREL (bupivacaine liposome injectable suspension), which claim it is not effective for pain management. The lawsuit seeks damages and retraction of the articles, accusing the ASA of publishing scientifically unsound conclusions while failing to disclose financial conflicts of interest. Pacira aims to remove these misleading materials to prevent confusion among healthcare stakeholders.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for Q1 2021: $114.7 million for EXPAREL and $3.3 million for iovera°. March sales reached $44.3 million for EXPAREL, marking a significant year-on-year increase. The company highlights U.S. regulatory approval for EXPAREL in pediatrics and a trend towards outpatient care, despite ongoing COVID-19 impacts on elective surgeries. Pacira plans to provide monthly sales updates to maintain transparency.
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced that the FDA has approved EXPAREL for use in children aged 6 and older, making it the first long-acting local analgesic for this age group. This approval expands EXPAREL's indication for single-dose infiltration for postsurgical pain management, addressing a critical need for non-opioid alternatives in pediatric care. The approval is based on positive data from the Phase 3 PLAY study, which involved 98 pediatric patients. The company aims to reduce opioid exposure among children undergoing surgery.
Pacira BioSciences, Inc. (Nasdaq: PCRX) reported preliminary unaudited net product sales of EXPAREL at $35.6 million for February 2021, with average daily sales at 103% compared to last year. Despite ongoing COVID-19 challenges, the company observed strong demand for non-opioid pain management solutions, especially in outpatient settings. The impact of the pandemic continues to affect elective surgeries, but Pacira remains focused on leveraging EXPAREL and iovera° to enhance market presence. The company plans to report monthly sales data to provide transparency.
PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 2021 Barclays Global Healthcare Conference on March 9, 2021, at 10:55 AM ET. Interested parties can access the live audio from the company’s website's Events page, with a replay available for two weeks post-event. Pacira leads in non-opioid pain management solutions, notably with its long-acting local analgesic, EXPAREL®, launched in April 2012. The company aims to reduce opioid reliance, further emphasized by its acquisition of the iovera°® cryoanalgesia device in April 2019.
Pacira BioSciences (PCRX) reported record full-year 2020 revenue of $429.6 million, a 2% increase from 2019. The fourth quarter revenue reached $131.0 million, up 7% year-over-year. GAAP net income for the year was $145.5 million, or $3.41 per share. Despite challenges from the COVID-19 pandemic, EXPAREL sales drove strong growth, reaching $413.3 million. The European Commission approved EXPAREL for post-surgical pain, expanding market opportunities. Pacira remains committed to opioid alternatives amid the ongoing opioid crisis.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its fourth quarter and full year 2020 financial results on February 25, 2021, before U.S. market opening. A live conference call and webcast will follow at 8:30 a.m. ET, with participation accessible via a dedicated phone line and on their website. Pacira is committed to non-opioid pain management, focusing on its long-acting local analgesic, EXPAREL®, launched in 2012, and the iovera°® cryoanalgesia device acquired in 2019.
Pacira BioSciences reported preliminary unaudited net product sales of EXPAREL and iovera° totaling $34.9 million and $1.1 million, respectively, for January 2021. Average daily sales for EXPAREL reached 108% of the prior year, signaling ongoing growth despite COVID-19 challenges. The company emphasizes the successful adoption of EXPAREL in elective surgeries and its relevance in expedited recovery protocols. However, COVID-19 continues to negatively impact elective surgical schedules, affecting overall sales.
Pacira BioSciences (Nasdaq: PCRX) announced an equity investment in GeneQuine Biotherapeutics to support gene therapy development for osteoarthritis. The initial investment is €2 million, with an additional €4 million contingent on achieving specific milestones related to its lead product, GQ-303. Up to €2.5 million will be in convertible notes. This investment aligns with Pacira's mission to advance non-opioid pain management solutions. GeneQuine’s gene therapy vectors aim to enhance joint function and reduce pain and inflammation.